Palomar projects $10-15 mil. in Epilaser sales for remainder of 1996.
This article was originally published in The Gray Sheet
PALOMAR EPILASER WILL GENERATE $10-15 MIL. IN REVENUE by the end of calendar 1996, Chairman and CEO Steven Georgiev said at a July 15 investor conference held in New York City. FDA cleared the firm's 510(k) on July 12 for a broad range of dermatological applications such as the removal of pigmented lesions, tattoos, skin lesions and birth marks.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.